UK markets closed

Siemens Healthineers AG (SHL.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
64.02-0.98 (-1.51%)
At close: 05:35PM CET
Full screen
Previous close65.00
Open64.66
Bid64.20 x 0
Ask64.24 x 0
Day's range63.58 - 65.02
52-week range39.00 - 67.50
Volume752,547
Avg. volume800,582
Market cap72.426B
Beta (5Y monthly)0.45
PE ratio (TTM)40.78
EPS (TTM)1.57
Earnings date31 Jan 2022 - 04 Feb 2022
Forward dividend & yield0.80 (1.24%)
Ex-dividend date15 Feb 2021
1y target est67.38
  • Business Wire

    Siemens Healthineers and Prisma Health Join Forces to Innovate Healthcare for South Carolina

    GREENVILLE, S.C. & MALVERN, Pa., Jun 22, 2021--Siemens Healthineers and Prisma Health announced today a 10-year strategic relationship to help create a better state of health for South Carolina. This Value Partnership is focused on healthcare innovation, workforce development, and improving health care for patients and communities served by Prisma Health. Through this relationship, Siemens Healthineers and Prisma Health will deploy the latest generation of medical technology at all Prisma Health

  • EQS Group

    Siemens Healthineers AG: Q1 results significantly better than market expectations; Outlook for FY2021 raised

    Siemens Healthineers AG / Key word(s): Change in Forecast/Quarterly / Interim StatementSiemens Healthineers AG: Q1 results significantly better than market expectations; Outlook for FY2021 raised26-Jan-2021 / 19:47 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Q1 results significantly better than market expectations; Outlook for FY2021 raisedBased on our broad portfolio and strong global presence we were able to meet pandemic-related demands. At the same time, our assumption for a further normalization of demand for standard procedures to pre-pandemic levels has been re-affirmed. The combination of these two factors was the basis for a very strong performance in Q1 FY2021.- Revenue: €3,868 m (PY: €3,587 m), comparable growth +13.3% y-o-y- Adjusted EBIT: €738 m (PY: €487 m)- Adjusted EBIT margin: 19.1% (PY: 13.6%)- Adjusted basic earnings per share: €0.49 (PY: €0.36)ImagingWith a very strong start into the fiscal year, the Imaging segment benefitted from growth in all business lines. In particular the business line Computed Tomography posted clear double-digit growth y-o-y, with products for pandemic-related demands contributing significantly.- Revenue: €2,319 m (PY: €2,221 m), comparable growth +9.3% y-o-y- Adjusted EBIT: €542 m (PY: €387 m)- Adjusted EBIT margin: 23.4% (PY: 17.4%)DiagnosticsThe Diagnostics segment saw a significant contribution from pandemic-related products, in particular the rapid antigen test of our point of care business generated €130 million of revenues. The core business saw a return to growth.- Revenue: €1,183 m (PY: €1,013 m), comparable growth +23.5% y-o-y- Adjusted EBIT: €137 m (PY: €32 m)- Adjusted EBIT margin: 11.6% (PY: 3.1%)Advanced TherapiesThe segment Advanced Therapies saw a return to good revenue growth.- Revenue: €412 m (PY: €404 m), comparable growth +6.3% y-o-y- Adjusted EBIT: €78 m (PY: €79 m)- Adjusted EBIT margin: 18.8% (PY: 19.6%)Siemens Healthineers OutlookThe managing board decided today to raise the outlook for FY2021 to 8% - 12% comparable revenue growth (from previously 5% - 8%) and to increase the expected adjusted basic earnings per share range to 1.63 - 1.82 € per share (from previously 1.58 - 1.72 €).The conversion from the additional revenues to earnings per share will be softened by higher expenses for variable compensation and stronger FX headwinds versus the previous guidance.The outlook was raised based on the ongoing pandemic related demands and a higher confidence in the normalization of the underlying business. The assumption for the rapid antigen test revenues now is for €300-350 million revenues (versus the previous assumption of about €100 million revenues). Given the dynamic of the pandemic, we assume that the pandemic-related demand from Q1 will not persist to the same extent through the remaining FY2021 and beyond. The further assumptions of the previous outlook remain unchanged.Siemens Healthineers will publish its full earnings release for the Q1 of FY2021 on February 1, 2021.Please find further explanations regarding our financial key performance indicators in chapter "A.2 Financial performance system" and in the notes to the consolidated financial statements note 29 "Segment information" in the Annual Report 2020 of Siemens Healthineers. The document can be found under the following internet link https://www.corporate.siemens-healthineers.com/investor-relations/presentations-financial-publications . Contact:Marc KoebernickHead of Investor RelationsHenkestr. 12791052 Erlangen+49 (0) 9131-84-2676marc.koebernick@siemens-healthineers.com26-Jan-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Siemens Healthineers AG Henkestr. 127 91052 Erlangen Germany Phone: +49 800 188 188 5 Fax: +49 9131 844552 E-mail: contact@healthcare.siemens.com Internet: https://www.corporate.siemens-healthineers.com ISIN: DE000SHL1006 WKN: SHL100 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1163498 End of Announcement DGAP News Service

  • EQS Group

    Siemens Healthineers AG: Disclosure pursuant to art. 5 para. 1 lit. b), para. 3 of the Regulation (EU) no. 596/2014 (MAR) and Art. 2 para. 3 of the Delegated Regulation (EU) No. 2016/1052

    DGAP-News: Siemens Healthineers AG / Key word(s): Share Buyback25.01.2021 / 17:16 The issuer is solely responsible for the content of this announcement.Disclosure pursuant to art. 5 para. 1 lit. b), para. 3 of the Regulation (EU) no. 596/2014 (MAR) and Art. 2 para. 3 of the Delegated Regulation (EU) No. 2016/1052Share buyback - 8th Interim Reporting In the time period from and including 18 January 2021 until and including 22 January 2021, a number of 131,964 shares of Siemens Healthineers AG were bought back within the framework of the share buyback of Siemens Healthineers AG; on 03 October 2020, Siemens Healthineers AG disclosed pursuant to Art. 5 para. 1 lit. a) of the Regulation (EU) No. 596/2014 (MAR) and Art. 2 para. 1 of the Delegated Regulation (EU) No. 2016/1052 the start of the share buyback on 07 October 2020.Shares were bought back as follows: Day of purchase Aggregated volume of shares Weighted average price 01/20/2021 27,411 44.4576 01/21/2021 55,082 44.6668 01/22/2021 49,471 44.5061 The transactions are published in a detailed form on the website of Siemens Healthineers AG (www.corporate.siemens-healthineers.com/investor-relations).The total volume of shares which were bought back within the framework of the share buyback in the time period from and including 07 October 2020 until and including 22 January 2021 amounts to 3,487,877 shares.The purchase of the shares of Siemens Healthineers AG is carried out by a credit institution that has been commissioned by Siemens Healthineers AG; the shares are repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA).Munich, 25 January 2021Siemens Healthineers AGThe Managing Board25.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Siemens Healthineers AG Henkestr. 127 91052 Erlangen Germany Phone: +49 800 188 188 5 Fax: +49 9131 844552 E-mail: contact@healthcare.siemens.com Internet: https://www.corporate.siemens-healthineers.com ISIN: DE000SHL1006 WKN: SHL100 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1163093 End of News DGAP News Service